Narlumosbart Biosimilar - Research Grade

Human

TNFSF11

5mg/ml

Human IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH2922

O14788

Blue ice

TNFSF11, better known as RANKL, is the principal driver of osteoclast differentiation and a central regulator of bone remodelling and immune signalling. This anti-human TNFSF11 recombinant monoclonal antibody is offered as an unconjugated, non-therapeutic analog of narlumosbart for research use only. Built to demanding in vivo specifications, it is purified to a low-endotoxin standard and manufactured in scalable milligram (mg) to gram (g) quantities suited to bulk and high-throughput work. Researchers can apply it as a dependable control and active reagent in bone biology assays, osteoclastogenesis studies, in vitro neutralization screens, and in vivo skeletal disease models.

Detects human TNFSF11

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks